Stay updated with breaking news from Excalibur health. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Real world patient database and revenues rapidly growing Sensyne poised for accelerated international growth
Oxford, U.K. 27 May 2021: Sensyne Health plc (LSE: SENS) ( Sensyne or the Company ), the Clinical AI company, today announces an update on trading for the financial year ended 30 April 2021 ( FY 2021 ), and an outlook statement.
UPDATE ON TRADING · Robust financial performance: FY 2021 unaudited revenues of at least £9.0 million (FY 2020: £2.1 million audited). · Strong revenue growth driven by contracts with life sciences companies, with recognition of the majority of the £4.8 million minimum revenues from MagnifEye AI technology contract with Excalibur Health Services ( Excalibur ). · Cash and cash equivalents were £23.6 million (unaudited) and excludes receipt of majority of minimum revenue payments from the Exca ....
UK small-cap shares: 2 Covid-19-related stocks I’d buy right now More on: Sensyne Health (LSE: SENS). Both stocks have links to the coronavirus pandemic. Covid-19 is far from over and I think these companies could be a great way to play this theme. #1 – Synairgen Synairgen is a UK small-cap share that I think is taking a very different stance on Covid-19. Rather than developing a vaccine, it’s developing a treatment called SNG001. US$12.3 TRILLION out of thin air… And if you click here we’ll show you something that could be key to unlocking 5G’s full potential. ....